RxDoctor Payments Data

Steven Kessler, DO

Gastroenterology · Chattanooga, TNNPI 1689611626

Payments from drug & device makers

$11,577in general payments, 2019–2025

Across 490 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$758
  • Johnson & Johnson$676
  • Takeda Pharmaceuticals U.S.A., Inc.$645
  • Boston Scientific$595
  • Regeneron Healthcare Solutions, Inc.$464
  • plus $5K from 40 others

What the payments were for

  • Travel & lodging$2562%
  • Food & beverage$9,97997%
  • Education$430%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,577 in reported general payments places this provider in the 75th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$82,388
Medicare patients
383
Services billed
722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab21$561,133
Humira(Cf) PenAdalimumab24$169,063
LinzessLinaclotide113$79,147
Budesonide EcBudesonide21$17,172
ClenpiqSod Picosulf/Mag Ox/Citric Ac57$9,753
Dexlansoprazole DrDexlansoprazole35$9,101
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates49$2,871
Pantoprazole Sodium242$2,647
Budesonide DrBudesonide16$2,526
Proctofoam-HcHydrocortisone/Pramoxine11$1,970
Lubiprostone21$1,936
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,770
Omeprazole91$1,470
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine51$1,137
Sucralfate18$861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$676$561,13321 claims
AbbVieLinzess$3,522$79,147113 claims
Ferring Pharmaceuticals Inc.Clenpiq$215$9,75357 claims
Braintree Laboratories, Inc.Sutab$53$1,77011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →